A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: Therapeutic and heuristic implications

Psychopharmacology

Volumn 171, Issue 4, 2004, Pages 365-374

  Jaskiw, George E ^a,b   Popli, Anand P ^c,d  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Antipsychotic drugs; Dopa; Meta analysis; Schizophrenia

Indexed keywords

LEVODOPA; NEUROLEPTIC AGENT;

CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EVALUATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS; HUMANS; LEVODOPA; MIDDLE AGED; SCHIZOPHRENIA;

EID: 1042288631     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1672-y     Document Type: Review

References (97)

1. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109
2. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719
3. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589
4. Alpert M, Friedhoff AJ, Marcos LR, Diamond F (1978) Paradoxical reaction to L-dopa in schizophrenic patients. Am J Psychiatry 135:1329-1332
5. Andreasen NC (1985) Negative syndrome in schizophrenia: strategies for long-term management. Adv Biochem Psychopharmacol 40:1-7
6. Angrist B, Sathananthan G, Gershon S (1973) Behavioral effects of L-dopa in schizophrenic patients. Psychopharmacologia 31:1-12
7. Asano T, Noma T, Matsuda K, Ikeda H, Otsuki S (1973) Effect of L-dopa on the hypochondriac complaints of the chronic psychotics. Seishin Igaku (in Japanese) 15:745-751
8. Benkert O, Muller-Siecheneder F, Wetzel H (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5:43-53
9. Beramendi V, Alpert M, Guimon J, Friedhoff A, Gutierrez M (1980) [Controlled study of L-dopa in schizophrenia with reference to the theory of hypersensitivity of dopamine receptors]. Arch Neurobiol (Madr) 43:107-124
10. Berman KF, Weinberger DR (1990) The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits. Prog Brain Res 85:521-536
11. Brambilla F, Scarone S, Ponzano M, Maffei C, Nobile P, Rovere C, Guastalla A (1979) Catecholaminergic drugs in chronic schizophrenia. Neuropsychobiology 5:185-200
12. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de BA, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574
13. Buchanan FH, Parton RV, Warren JW, Baker EP (1975) Double blind trial of L-dopa in chronic schizophrenia. Aust N Z J Psychiatry 9:269-271
14. Bunney WEJ, Brodie HK, Murphy DL, Goodwin FK (1971) Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 127:872-881
15. 2 receptors. J Pharmacol Exp Ther 302:381-389
16. Buu NT (1989) Vesicular accumulation of dopamine following L-dopa administration. Biochem Pharmacol 38:1787-1792
17. Calil HM, Yesavage JA, Hollister LE (1977) Low dose levodopa in schizophrenia. Commun Psychopharmacol 1:593-596
18. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR (2000) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 157:1646-1651
19. Carey RJ, Pinheiro-Carrera M, Dai H, Tomaz C, Huston JP (1995) L-Dopa and psychosis: evidence for L-dopa-induced increases in prefrontal cortex dopamine and in serum corticosterone. Biol Psychiatry 38:669-676
20. Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13:141-178
21. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526
22. Chen JP, Ruan D, Paredes W, Gardner EL (1992) Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats. Brain Res 571:235-241
23. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
24. Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137:16-21
25. Chouinard G, Annable L, Mercier P, Turnier L (1987) Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 23:221-226
26. Cumming P, Kuwabara H, Ase A, Gjedde A (1995) Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem 65:1381-1390
27. Cumming P, Ase A, Laliberte C, Kuwabara H, Gjedde A (1997) In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J Cereb Blood Flow Metab 17:1254-1260
28. Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) L-Dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934-938
29. Dolphin A, Jenner P, Marsden CD (1976) Noradrenaline synthesis from L-dopa in rodents and its relationship to motor activity. Pharmacol Biochem Behav 5:431-439
30. Dunner DL, Fieve RR (1975) Affective disorder: studies with amine precursors. Am J Psychiatry 132:180-183
31. Ebert B, Madsen U, Lund TM, Lenz SM, Krogsgaard-Larsen P (1994) Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5-phenyl-4- isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPA. Neurochem Int 24:507-515
32. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Move Disord 14:484-487
33. Fleming P, Makar H, Hunter KR (1970) Levodopa in drug-induced extrapyramidal disorders. Lancet 2:1186
34. Friedman JI, Adler DN, Davis KL (1999) The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry 46:1243-1252
35. Garfinkel PE, Stancer HC (1976) L-Dopa and schizophrenia. Can Psychiatr Assoc J 21:27-29
36. Gerlach J, Luhdorf K (1975) The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo. Psychopharmacologia 44:105-110
37. Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52:173-188
38. Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159:1395-1402
39. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
40. Grace AA (1993) Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect 91:111-134
41. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26:119-136
42. Gutierrez M, Alpert M, Guimon J, Friedhoff AJ, Veramendi V (1979) [Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 7:181-188
43. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
44. Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, Orlando, Fla.
45. Hoffmann H, Kupper Z, Zbinden M, Hirsbrunner HP (2003) Predicting vocational functioning and outcome in schizophrenia outpatients attending a vocational rehabilitation program. Soc Psychiatry Psychiatr Epidemiol 38:76-82
46. Inanaga K, Tanaka M (1973) Effects of L-dopa on schizophrenia. In: Ban TA (ed) Psychopharmacology, sexual disorders and drug abuse. North Holland Publishing Co., Amsterdam, pp 229-233
47. Inanaga K, Oshima M, Tachibana H, Nakamura K, Koketsu K (1971) Three cases of schizophrenia treated with L-dopa. Kurume Med J 18:161-168
48. Inanaga K, Inoue K, Tachibana H, Oshima M, Kotorii T (1972) Effect of L-dopa in schizophrenia. Folia Psychiatr Neurol Jpn 26:145-157
49. Inanaga K, Nakazawa Y, Inoue K, Tachibana H, Oshima M (1975a) Double-blind controlled study of L-dopa therapy in schizophrenia. Folia Psychiatr Neurol Jpn 29:123-143
50. Inanaga K, Ohshima M, Nagata T, Yamauchi I (1975b) Behavioral effects of L-dopa and thyrotropin-releasing hormone in schizophrenic patients: a preliminary report. Folia Psychiatr Neurol Jpn 29:197-205
51. Kai Y (1976) The effect of L-dopa and vitamin B6 in schizophrenia. Folia Psychiatr Neurol Jpn 30:19-26
52. Kapur S, Remington G (2001) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873-883
53. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369
54. Kato T, Karai N, Katsuyama M, Nakamura M, Katsube J (1987) Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa. Biochem Pharmacol 36:3051-3057
55. Kawamura T, Asada N, Kimura N, Tsukue I (1971) Psychiatric clinical findings of L-dopa effect, especially for psychic symptom and drug-induced parkinsonian symptoms in schizophrenia. Shinryo Shinyaku (in Japanese) 24:826-851
56. Kay SR, Opler LA (1985) L-Dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. Int J Psychiatr Med 15:293-298
57. Kolachana BS, Saunders RC, Weinberger DR (1995) Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience 69:859-868
58. Laruelle M, Abi-Dargham A (1999) Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13:358-371
59. Lehrman NS, Sharav VH (1997) Ethical problems in psychiatric research. J Ment Health Admin 24:227-250
60. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681-688
61. Loeffler DA, LeWitt PA, Juneau PL, Camp DM, Arnold LA, Hyland K (1998) Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation. Brain Res Bull 47:663-667
62. Ludatscher JI (1989) Stable remission of tardive dyskinesia by L-dopa. J Clin Psychopharmacol 9:39-41
63. Matthysse S, Smith EL, Puck TT, Edelman GM (1972) Prospects for research on schizophrenia. VI. Biochemical hypotheses and new techniques. Neurosci Res Program Bull 10:446-455
64. Meltzer HY (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18:515-542
65. Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6:329-338
66. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 12:39-45
67. Mendels J, Stinnett JL, Burns D, Frazer A (1975) Amine precursors and depression. Arch Gen Psychiatry 32:22-30
68. Misu Y, Goshima Y, Ueda H, Okamura H (1996) Neurobiology of L-dopaergic systems. Prog Neurobiol 49:415-454
69. Nguyen TB, Angers M (1987) Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain. Biochem Pharmacol 36:1731-1735
70. Nishikawa K, Higashayama I, Kasahara T (1972) L-Dopa treatment of chronic schizophrenia. Shinryo Shinyaku (in Japanese) 9:1439-1450
71. Ogura C, Kishimoto A, Nakao T (1976) Clinical effect of L-dopa on schizophrenia. Curr Ther Res Clin Exp 20:308-318
72. Opacka-Juffry J, Brooks DJ (1995) L-Dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. Mov Disord 10:241-249
73. Oren DA, Moul DE, Schwartz PJ, Wehr TA, Rosenthal NE (1994) A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis. J Clin Psychopharmacol 14:196-200
74. Otsuka T, Kumashioro E, Mizushima S, Maruko K, Koizumi S, Unno Y (1974) Effect of L-dopa on schizophrenia. Rinsho Seishin Igaku (in Japanese) 3:629-637
75. Perlstein WM, Carter CS, Noll DC, Cohen JD (2001) Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 158:1105-1113
76. Pidgeon JF, Wolf MA (1989) [Dopaminergic agonists and schizophrenia] Agonistes dopaminergiques et schizophrenie. Psychiatr J Univ Ott 14:529-535
77. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91:11651-11654
78. Rosenthal B, Rosnow R (1991) Essentials of behavioral research: methods and data and analysis, 2nd edn. McGraw-Hill, New York
79. Sarai K, Kumura N, Ishii T, Iseki K, Imada HK, Kawamura T, Kino M, Echigo T (1973) Possibility of amine precursor therapy on schizophrenics by experimental study with L-dopa. Seishin Igaku (in Japanese) 15:189-196
80. Sathananthan G, Angrist BM, Gershon S (1973) Response threshold to levodopa in psychiatric patients. Biol Psychiatry 7:139-146
81. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3:123-134
82. Shingu K, Kawai I, Yamada K (1979) Three cases of unipolar delusional depression responsive to L-dopa. Folia Psychiatr Neurol Jpn 33:511-515
83. Tamminga CA, Carlsson A (2002) Partial dopamine agonists and dopaminergic stabilizers in the treatment of psychosis. Curr Drug Target CNS Neurol Disord 1:141-147
84. Tedroff JM (1997) The neuroregulatory properties of L-dopa. A review of the evidence and potential role in the treatment of Parkinson's disease. Rev Neurosci 8:195-204
85. 11C]-L-3,4- dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography. Acta Neurol Scand 85:166-173
86. 11C]raclopride displacement and PET. Neurology 46:1430-1436
87. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, O'Brien CF, LeWitt PA, Koller WC (1998) Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Move Disord 13:377-382
88. Turner W, Merlis S (1964) A clinical trial of pargyline and dopa in psychotic subjects. Dis Nerv Syst 25:538
89. van Kammen D, Kelley M (1991) Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr Res 4:173-191
90. White FJ, Wang RY (1983) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 32:983-993
91. Wolkowitz OM (1993) Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 5:79-90
92. Yamauchi I (1972) Effects of L-dopa on schizophrenia. Seishin Igaku 14:941-949
93. 6 on electroencephalograms of schizophrenic patients: a preliminary report. Folia Psychiatr Neurol Jpn 30:121-151
94. Yaryura-Tobias JA, Diamond B, Merlis S (1970a) The action of L-dopa on schizophrenic patients (a preliminary report). Curr Ther Res Clin Exp 12:528-531
95. Yaryura-Tobias JA, Wolpert A, Dana L, Merlis S (1970b) Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst 31:60-63
96. Yaryura-Tobias JA, Diamond B, Merlis S (1971) Verbal communication with L-dopa treatment. Nature 234:224-225
97. 11C]raclopride. Neuropsychopharmacology 27:248-259